




Correlative Science Directed CALGB Lung Cancer Studies (Part 3 of 3)

Robert Kratzke, MD
University of Minnesota

CALGB CRA Continuing Education Workshop, June 2007

For CALGB Participants Only

An Opportunity to Improve Therapeutic Outcome




Schiller et al., NEJM 346: 92 (2002)

For CALGB Participants Only

Slide 2

A Strategy to Predict Response to Cytotoxic Chemotherapy








- Identify resistant and sensitive cells
- Build expression predictor of response



For CALGB Participants Only

Slide 3

Methodology







CALGB studies using molecular predictors for prognosis and response to therapy

- Stage 4 NSCLC pharmacogenomic study
 - CALGB 307XX
- Stage 1a adjuvant therapy study
 - CALGB 30506
- Stage 4 NSCLC molecular array directed study
 - In development

For CALGB Participants Only

Slide 15

Array based predictors of lung cancer prognosis and therapy

- DNA arrays allow examination of all expressed mRNA transcripts
- Multiple gene signature studies have been carried out in lung cancer
- CALGB will be launching prospective therapy trials based on array data

For CALGB Participants Only

Slide 16